<DOC>
	<DOCNO>NCT01097941</DOCNO>
	<brief_summary>A total 51 child age 4 9 randomize receive two dose schedule either license live attenuate A/California/07/09 influenza vaccine ( LAIV ) license inactivated A/California/07/09 influenza vaccine ( IIV ) IIV follow LAIV separate 28 day . Children prior vaccination natural infection novel H1N1 influenza exclude . Randomization stratify pre-existing HAI titer previous winter 's seasonal H1N1 A/Brisbane/57/07 reference virus .</brief_summary>
	<brief_title>Effect Age Prior Immunity Response H1N1 Vaccines Children</brief_title>
	<detailed_description>The study conduct randomize , prospective , open-label evaluation clinical tolerability , vaccine virus shed , serum mucosal antibody response vaccination either live monovalent novel H1N1 influenza vaccine ( LAIV ) monovalent inactivate novel H1N1 influenza vaccine ( IIV ) healthy child age 4 9 year . Children screen antibody A/Brisbane/57/07 ( H1N1 ) A/California/07/09 ( H1N1 ) prior randomization . Children evidence prior exposure 2009 pandemic H1N1 virus exclude . Those antibody A/Brisbane/57/07 ( H1N1 ) stratify preexist antibody . Vaccine administered day 0 28 . Safety vaccination assess use symptom collect parent 7 day dose vaccine . Serum obtain prior day 28 follow dose vaccine assess antibody HAI , ELISA , B-cell ELISPOT neutralization technique . Nasal secretion obtain nasal aspiration prior day 28 dose assess HA-specific IgA antibody ELISA . Nasal swabs obtain day 2 , 4 , 7 dose live vaccine assess presence magnitude vaccine virus shed live attenuate vaccine rtRT-PCR TCID50 MDCK cell .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 4 9 year , inclusive . Prevaccination serum HAI titer A/California/07/09 8 less No prior history laboratory document infection novel H1N1 virus immunization novel H1N1 vaccine . good health , determine : vital sign ( heart rate &lt; 140 bpm ; blood pressure : systolic ≥ 90 mm Hg ≤140 mm Hg ; diastolic ≤ 90 mm Hg ; oral temperature &lt; 100.0ºF ) ; medical history ; target physical examination , necessary , base medical history . Stable medical condition define : recent increase prescription medication , dose , frequency medication last 3 month health outcome specific disease consider within acceptable limit last 6 month . subject/parents able understand comply plan study procedure , include available study visit . subject/parents provide informed consent prior study procedure . ( An assent obtain child 6 year old ) previous history vaccination novel H1N1 virus laboratory document history previous novel H1N1 infection . History egg allergy allergy component vaccine . History wheeze . immunosuppressed result underlie illness treatment immunosuppressive cytotoxic drug , use anticancer chemotherapy radiation therapy . active neoplastic disease . longterm ( great 2 week ) use oral parenteral steroid , highdose inhaled steroid ( &gt; 800 mg/day beclomethasone dipropionate equivalent ) within precede 6 month ( nasal topical steroid allow ) . receive immunoglobulin another blood product within 3 month prior enrollment study . receive inactivated vaccine within 2 week live vaccine within 4 week prior enrollment study plan receive another vaccine within next 28 day ( 56 day vaccine naïve recipient ) . acute chronic medical condition , opinion investigator , would render vaccination unsafe would interfere evaluation response . These condition include chronic condition recognize risk factor influenza complication contraindication live vaccination , include chronic cardiac ( exclusive hypertension ) pulmonary condition ( include asthma ) , diabetes mellitus , renal impairment . acute illness oral temperature great 99.9 degree F ( 37.7 degree C ) within 3 day prior enrollment vaccination . Subjects acute illness treat symptom resolve eligible enroll long treatment complete symptom resolve &gt; 3 day prior enrollment . currently participate plan participate study involve experimental agent ( vaccine , drug , biologic , device , blood product , medication ) receive experimental agent within 1 month prior enrollment study , expect receive another experimental agent participation study , intend donate blood study period . condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol . know human immunodeficiency virus , hepatitis B , hepatitis C infection . previous history GuillainBarré syndrome within 6 week receipt influenza vaccination . condition principal investigator ( PI ) believe may interfere successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>H1N1</keyword>
</DOC>